ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$178.09
Updated
AbbVie Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$159.62 |
52 Week High | US$182.89 |
52 Week Low | US$130.96 |
Beta | 0.56 |
1 Month Change | -11.49% |
3 Month Change | -2.91% |
1 Year Change | 5.62% |
3 Year Change | 43.16% |
5 Year Change | 102.80% |
Change since IPO | 356.06% |
Recent News & Updates
Recent updates
AbbVie's Q1: Positive Surprise
Apr 26AbbVie: Great To Be Proven Wrong - Still Not A Buy
Apr 14AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision
Apr 08AbbVie: Strong Cash Flow Growth Fuels Dividend Growth
Mar 08AbbVie: Things Are Getting Clearer
Feb 05AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade)
Jan 30AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.55
Jan 05AbbVie: Time To Lock In Gains (Rating Downgrade)
Jan 03AbbVie Vs. GSK: Dual Dominance In Pharma
Dec 23AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's
Dec 124.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024
Nov 29AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55
Nov 28AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks
Nov 21AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.55
Oct 30AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results
Oct 30AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans
Oct 23AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014
Oct 16Shareholder Returns
ABBV | US Biotechs | US Market | |
---|---|---|---|
7D | -4.1% | -0.2% | 2.9% |
1Y | 5.6% | -1.0% | 22.2% |
Return vs Industry: ABBV exceeded the US Biotechs industry which returned -1% over the past year.
Return vs Market: ABBV underperformed the US Market which returned 22.2% over the past year.
Price Volatility
ABBV volatility | |
---|---|
ABBV Average Weekly Movement | 2.9% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months.
Volatility Over Time: ABBV's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 50,000 | Rick Gonzalez | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
ABBV fundamental statistics | |
---|---|
Market cap | US$282.63b |
Earnings (TTM) | US$5.95b |
Revenue (TTM) | US$54.40b |
47.5x
P/E Ratio5.2x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABBV income statement (TTM) | |
---|---|
Revenue | US$54.40b |
Cost of Revenue | US$16.83b |
Gross Profit | US$37.57b |
Other Expenses | US$31.62b |
Earnings | US$5.95b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 3.36 |
Gross Margin | 69.06% |
Net Profit Margin | 10.94% |
Debt/Equity Ratio | 573.6% |
How did ABBV perform over the long term?
See historical performance and comparison